Research

Guggul

11 peer-reviewed studies curated from PubMed and Semantic Scholar.

0
Meta-analyses
1
Systematic reviews
9
RCTs
1
Other studies
Systematic reviews (9%)
RCTs (82%)

Studies

Sorted by quality and recency

2023·Frontiers in pharmacology·Meenakshi Gupta, Deepti Singh, Shruti Rastogi, et al

Anti-cancer activity of guggulsterone by modulating apoptotic markers: a systematic review and meta-analysis.

Systematic review

Systematic review and meta-analysis of guggulsterone's anticancer activity, summarizing its effects on various cancer cell lines by inducing apoptosis, inhibiting cell proliferation, and modulating signaling pathways. The review included 40 articles, with 23 in the meta-analysis, showing significant apoptotic effects across multiple cancer types.

PubMedRead on PubMed
2021·Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·Zobeiri Mehdi, Parvizi Fatemeh, Rahimi Roja, et al

Efficacy and safety of Hemoheal cream in patients with hemorrhoids: a randomized double-blind placebo controlled clinical trial.

RCTn = 52Inflammation

RCT evaluating the efficacy and safety of Hemoheal cream, an anti-hemorrhoid herbal preparation, in 52 patients with symptomatic hemorrhoids. The study found significant improvements in anal irritation, bleeding, pain, and swelling sense after 3 weeks of treatment compared to placebo. One patient reported rashes at the application site.

PubMedRead on PubMed
2020·Complementary medicine research·Francesco Donato, Elena Raffetti, Giuseppe Toninelli, et al

Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial.

RCTn = 90Heart Health -

RCT assessing the effects of Guggulu and Triphala on serum cholesterol in 90 individuals with hypercholesterolaemia. The intervention group showed a 3.3% decrease in total serum cholesterol, but no significant difference compared to placebo. No significant effects on LDL cholesterol, BMI, or waist circumference were observed.

PubMedRead on PubMed
2003·JAMA·Philippe O Szapary, Megan L Wolfe, LeAnne T Bloedon, et al

Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.

RCTn = 103Heart Health

Double-blind, randomized, placebo-controlled trial of guggulipid in 103 adults with hypercholesterolemia. Guggulipid raised LDL-C levels by 4-5% compared to placebo, with no significant changes in other cholesterol measures. Some participants developed a hypersensitivity rash.

PubMedRead on PubMed
2012·Therapie·Caroline Scholtes, Patrice André, Christian Trépo, et al

Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial.

RCTn = 15

Proof-of-concept trial testing the modulation of farnesoid X receptor activity using oral guggulsterone in hepatitis C virus genotype 1-infected patients who failed first-line therapy. The study examines the safety and efficacy by assessing blood viral loads.

PubMedRead on PubMed
2008·Complementary therapies in medicine·Lise Anett Nohr, Lars Bjørn Rasmussen, Jørund Straand

Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study.

RCTn = 34Heart Health

RCT in Norwegian general practice with 43 participants (34 completed) testing 2160mg guggul daily vs placebo for 12 weeks. Guggul significantly reduced total cholesterol and HDL-C compared to placebo, but not LDL-C, triglycerides, or total cholesterol/HDL-C ratio. Side effects included mild gastrointestinal discomfort, possible thyroid issues, and skin rash.

PubMedRead on PubMed
2003·Phytomedicine : international journal of phytotherapy and phytopharmacology·N Kimmatkar, V Thawani, L Hingorani, et al

Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial.

RCTn = 30Joint Bone Health

A randomized double blind placebo controlled crossover study assessed the efficacy, safety, and tolerability of Boswellia serrata Extract (BSE) in 30 patients with osteoarthritis of the knee. BSE treatment resulted in decreased knee pain, increased knee flexion, and increased walking distance, with statistically significant differences compared to placebo. BSE was well tolerated except for minor gastrointestinal adverse reactions.

PubMedRead on PubMed
1994·Cardiovascular drugs and therapy·R B Singh, M A Niaz, S Ghosh

Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia.

RCTn = 61Heart Health Inflammation

RCT comparing 50 mg guggulipid or placebo capsules twice daily for 24 weeks as adjuncts to a diet in 61 hypercholesterolemia patients. Guggulipid decreased total cholesterol, LDL, triglycerides, and oxidative stress markers, with no change in HDL levels. Side effects included headache, mild nausea, eructation, and hiccup.

PubMedRead on PubMed
1988·The Indian journal of medical research·S K Verma, A Bordia

Effect of Commiphora mukul (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol.

RCT

RCT studying the effect of Commiphora mukul (gum guggulu) in patients with hyperlipidemia, focusing on HDL-cholesterol levels.

PubMedRead on PubMed
1994·The Journal of dermatology·D M Thappa, J Dogra

Nodulocystic acne: oral gugulipid versus tetracycline.

RCTn = 20Skin Hair Health

RCT comparing the effects of oral gugulipid (25 mg guggulsterone) versus tetracycline (500 mg) in 20 patients with nodulocystic acne over 3 months. Both treatments reduced lesions significantly, with gugulipid showing a 68% reduction compared to 65.2% with tetracycline. The difference was not statistically significant. Patients with oily skin responded better to gugulipid.

PubMedRead on PubMed
2003·Alternative therapies in health and medicine·Betsy B Singh, Lakshmi C Mishra, Sivarama Prasad Vinjamury, et al

The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study.

Studyn = 30Joint Bone Health

Quasi-experimental study on the effectiveness of Commiphora mukul (guggul) for osteoarthritis of the knee in 30 participants. Significant improvements were observed in WOMAC total score and VAS pain scales after 1 and 2 months of supplementation, with no reported side effects.

PubMedRead on PubMed